• Today’s big news was the purchase of Curagen (CRGN) by Celldex Therapeutics (AVAN) for $94.5 million in an all-stock deal. I tell you, it was just so boring in the news today that we waited all day to post this deal at the top of our daily round-up. Snoooooozzzzz. [BioWorld]

• The FDA Oncologic Drugs Advisory Committee voted 10-3 for GSK and Genmab’s ARZERRA(TM) (ofatumumab). [Yahoo!Finance]

• The Street thinks it doesn’t look good for Hemisperx Biopharma’s Ampligen for treating chronic fatigue syndrome (CFS). [The Street]

• Elan up after BMS buy-in rumors! [MarketWatch]

• Is Matt Lauer really talking about Follica in this video? [stemcellbaldnesscures]

• Bausch & Lomb gets approval for Besivance, besifloxacin, for treating bacterial conjunctivitis…sigh. [US News & World Report]

• MediQuest gets $2.3M for Raynaud’s therapy. [Xconomy]

• Merck’s Singulair patent goes under the knife at the USPTO, again. [Yahoo!Finance]

• Finally, BNET Pharma does the ten weirdest drug stories of the month…hey, where’s IguanaBio???!!! [BNET Pharma]

Anonymous Tip? Comments? Contact us at: hr@iguanabio.com

Related Posts